Clinical Trial Update: Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Candida antigen and a bivalent HPV vaccine for treating multiple warts, sponsored by Zagazig University.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection
• Verruca Vulgaris

Drugs mentioned

• Candida antigen (candida antigen)
• Cervarix (human papillomavirus vaccine, bivalent)

Snippet

Sponsor: Zagazig University | Conditions: Warts, Human Papilloma Virus | Phase 2 | Status: RECRUITING